anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A cefradine tablet for treating infection caused by sensitive bacteria is disclosed. The main component of the cefradine tablet is 250 g of cefradine. Auxiliary materials of the cefradine tablet comprise 30-80 g of microcrystalline cellulose, 10-30 g of lactose, 10-20 g of carboxymethyl starch sodium, 2-8 g of magnesium stearate, 1-5 g of silicon dioxide, 0.5-2 g of potassium hydrogen tartrate, 2-5 g of hydroxypropyl methylcellulose, 2-8 g of number-IV polyacrylic resin, 1-5 g of magnesium stearate, 1-5 g of titanium dioxide, 1-5 g of talcum powder, 0.01-0.1 g of lemon yellow and 100-150 g of ethanol having a concentration of 95%. The cephalosporin for treating infection caused by sensitive bacteria, namely the cefradine tablet, has characteristics of significant curative effects, high targeting property, obvious efficacy, short treating time, and definite and significant curative effects for the infection caused by the sensitive bacteria. The cefradine tablet can enrich the market medicine variety so as to meet and guarantee medicine needs of people. The cefradine tablet is simple in production process, convenient in manufacturing, and low in cost.
PURPOSE: To quantify corneal cross-linking (CXL)-induced stiffening via mechanical testing to estimate the impact of changes in hydration levels (H) and evaluate depth-dependent tissue hydration after CXL.
METHODS: Eighty-three porcine corneal buttons were divided into three groups: Standard protocol CXL (S-CXL), accelerated CXL (A-CXL), and untreated (nonirradiated riboflavin-only) controls. Samples were hydrated or dehydrated to modulate H and dynamic mechanical analyzer compression tests were performed to measure Young's modulus (E). To extract the solid tissue network modulus, the cornea was modeled as a biphasic material after measuring E at different H. Corneal hydration was correlated with depth-dependent tissue thickness characterized by confocal reflection microscopy (CRM).
RESULTS: Young's modulus increased fourfold after S-CXL (0.72 ± 0.1 MPa) and threefold after A-CXL E (0.53 ± 0.12 MPa) versus controls (0.17 ± 0.045 MPa). However, H decreased from 4.07 ± 0.35 in controls to 2.06 ± 0.2 after S-CXL and 2.79 ± 0.12 after A-CXL. After H modulation and biphasic mechanical modeling, Young's modulus for corneal solid tissue network showed only a 1.8-fold increase after S-CXL (2.25 MPa) and 1.5-fold increase after A-CXL (1.85 MPa) versus controls (1.22 MPa). With CRM, the overall thickness of the corneal tissue was found to linearly correlate to hydration H as expected. No appreciable depth dependence of hydration-induced thickness changes throughout the corneal buttons were observed.
CONCLUSIONS: Corneal tissue hydration changes significantly impact measured corneal stiffness after CXL using mechanical testing. Not considering H leads to major overestimation of the stiffening effect of the CXL procedure. Depth-dependence of corneal thickness because of changing hydration is strongly dependent on the integrity of the tissue.
Breast cancer treatment encompasses various therapeutic modalities, including surgery, radiotherapy, and chemotherapy. Breast-conserving surgery has been an integral part of breast cancer management. However, radiotherapy, an important component of breast cancer management, can lead to complications, particularly fibrosis, affecting reconstructive surgery outcomes. We conducted an in vivo study using 48 female Wistar Albino rats, employing segmental mastectomy and radiotherapy to simulate post-mastectomy conditions. The rats were divided into six groups: control, mastectomy, mastectomy + radiotherapy, mastectomy + platelet-rich plasma (PRP) + radiotherapy, mastectomy + infliximab + radiotherapy, and mastectomy + infliximab + PRP + radiotherapy. Edema, hyperemia, inflammation, and fibrosis were assessed as indicators of tissue response. Histopathological analysis revealed that mastectomy + infliximab and mastectomy + infliximab + PRP groups showed significant reductions in fibrosis compared to other groups. Edema, hyperemia, and inflammation were also less severe in these groups compared to the control group. Radiotherapy-induced fibrosis is a major concern in breast reconstruction. Our study suggests that local PRP application and systemic infliximab administration, either alone or in combination, could mitigate the adverse effects of radiotherapy. This approach has the potential to improve reconstructive outcomes in patients undergoing or having the possibility to undergo radiotherapy. This is the first study showing the effectiveness of infliximab and PRP combination on wound healing. The provided experimental rat model might offer guidance for further research. This study provides insights into optimizing outcomes in reconstructive breast surgery, paving the way for further research and clinical studies.
For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
The present invention relates to immunology and describes a reagent in liquid form for inducing specific immunity against SARS-CoV-2, which contains a single active ingredient, including an expression vector of human adenovirus serotype 26 in which the E1 and E3 regions are deleted and the ORF6-Ad26 region is replaced by ORF6-Ad5, and has an integrated expression cassette selected from SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3. In another variant, the agent comprises a single active ingredient, including an expression vector of human adenovirus serotype 5 in which the E1 and E3 regions are deleted and which has an integrated expression cassette selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, and SEQ ID NO 3. In another variation, the agent comprises a single active ingredient, including an expression vector of simian adenovirus serotype 25 in which the E1 and E3 regions are deleted and which has an integral expression cassette selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 2, and SEQ ID NO. 3.
INTRODUCTION: Adolescents tend to experiment with ethanol which often results in heavy episodic drinking patterns leading to serious health concerns later in life. Chronic ethanol use damages renal tissue, promotes collagen deposition, and induces renal inflammation, thereby causing renal dysfunction. Therefore, an intervention such as simvastatin (a blood cholesterol-lowering drug) that could suppress the effects of ethanol on the kidney may be beneficial. This study explored the impact of simvastatin against the onset of renal morphological damage, fibrosis, and inflammation caused by ethanol exposure in mice.
MATERIALS AND METHODS: Ten four-week old C57BL/6J mice (F = 5; M = 5) were assigned to each experimental group: (I) NT; no administration of ethanol or simvastatin; (II) EtOH; 2.5 g/kg/day of 20% ethanol, intraperitoneal injection (i.p.); (III) SIM; 5 mg/kg/day of simvastatin, orally; (IV) EtOH + SIM5; 5 mg/kg/day of simvastatin, orally, followed by 2.5 g/kg/day of 20% ethanol, i.p.; and (V) EtOH + SIM15; 15 mg/kg/day of simvastatin, orally, followed by 2.5 g/kg/day of 20% ethanol, i.p. After the 28-day treatment period, the right kidney was removed and processed for haematoxylin and eosin staining, Masson's trichrome staining, or tumour necrosis factor-alpha (TNF-α) immunohistochemistry. The renal corpuscular area, glomerular area, and urinary space area were measured and the area of collagen or TNF-α expression was quantified using ImageJ software.
RESULTS: Ethanol administration significantly increased the renal corpuscular area, the glomerular area, the area of collagen, and the area of tissue with TNF-α immunoreactivity but decreased the area of urinary space. Simvastatin generally suppressed the ethanol effects in both sexes, although to varying degrees.
CONCLUSIONS: Simvastatin proved to suppress collagen deposition and the TNF-α production induced by ethanol in the kidney of mice thus indicating its effectiveness in the treatment of ethanol-related renal diseases.
Before the study, ethical approval was obtained from Marmara University Faculty of Medicine Ethics Committee with the number 09.2024.611. The study was started with 24 national athletes from Kocaeli Metropolitan Municipality Kağıtspor Team and was carried out on 23 athletes after one athlete in the control group was injured. The athletes who were examined by an ophthalmologist before the study, who did not have any visual problems and who did not have any surgical operation and/or injury history that would adversely affect the balance in the last 6 months were randomly divided into 2 groups. The 12-member vision training group was subjected to a vision training programme that included eye exercises accompanied by a physiotherapist for 3 sessions per week in addition to their routine training for 4 weeks, while the control group continued their routine training. At the beginning of the study (week 0) and at the end of the training (week 4), 't ruler-nelson hand reaction test', 'sit \& lie flexibility test' were performed by another physiotherapist, and 'snellen test' measurements were performed by an ophthalmologist for 'visual acuity' evaluation of the athletes. The researcher who performed the reaction time and flexibility measurements and the physician who assessed visual acuity performed the measurements without knowing which group the athletes were in. After statistically homogeneous-normality evaluation of the groups, Independent Sample t Test was used for comparison of descriptive characteristics between the groups. Mixed-order analysis of variance (ANOVA) was used to compare the variables in the groups according to the follow-up times. Bonferroni correction was applied for the comparison of main effects in the analyses. p\<0.05 was considered statistically significant.
The duration of infusion may vary with the dose (100 to 200 mg/day), but is usually one to four hours. A recommended minimum infusion time for 100 mg of a 0.5 mg/mL solution is one hour. Therapy should be continued for at least 24 to 48 hours after symptoms and fever have subsided. The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage. 

Intravenous solutions should not be injected intramuscularly or subcutaneously. Caution should be taken to avoid the inadvertent introduction of the intravenous solution into the adjacent soft tissue.
The invention discloses a novel <18>F-marked pyrazolo[1,5-a]pyrimidine compound. The compound is characterized by having a parent structure 3-cyan pyrazolo[1,5-a]pyrimidine, wherein the fifth bit of the compound has substituents R, namely methyl, chloromethyl, (N,N-dimethylamino)methyl, acetoxymethyl, hydroxymethyl and carboxyl; amido on the seventh bit of the compound is connected with fluorine-18 through a carbon chain with n carbon atoms; and the structure of the compound is shown as a formula A. The compound is simple to synthesize and mark with operation easiness. The compound can maintain higher concentration for a longer time in a tumor tissue, and has low absorption rate or high clearing rate in normal tissues and blood. In particular, the compound has very high ratios of tumor to blood ratio and tumor to muscle tissues. The invention also relates to application of the compound serving as a PET (Polyethylene Terephthalate) brain tumor developer. In a formula A of the compound, R=CH3, CH2Cl, CH2N(CH3)2, CH2OCOCH3 and CH2OH; and COOHn=2,3.
An aspect of the present invention provides a method for producing a fermented byproduct of soybeans. The method includes the steps of sterilizing a soybean byproduct with a moisture content of 40-65%; fermenting the soybean byproduct after inoculating a strain for fermentation into the sterilized soybean byproduct at 20-35°C for 5-20 days while the moisture content is maintained to be 40-65%; and drying the fermented byproduct of soybeans. According to the present invention, the fermented byproduct of soybeans is fermented by a certain aspergillus genus under a certain condition. Therefore, the fermented byproduct of soybeans has various functions enhanced compared with those of the byproduct prior to fermentation. According to the present invention, the fermented byproduct of soybeans has functions of alleviating damage on a liver or obesity, reducing LDL-cholesterol, or increasing HDL-cholesterol. Therefore, the fermented byproduct of soybeans is highly advantageous as a material for medicines and functional food. Moreover, the fermented byproduct of soybeans has a high added-value and thus can provide an economically positive effect.
The invention relates to the field of biodegradable macromolecule, and aims at providing a preparation method of biodegradable supermolecule polylactic acid microspheres. The method comprises the steps that 2-carbamido-4-[1H]-pyrimidone (UPy) end group modified polylactic acid is dissolved in good solvent, poor solvent is dropwise added under the stirring condition; after stirring continues to be conducted, centrifugal washing is conducted, and solid precipitates are collected; vacuum drying is conducted, and then the biodegradable supermolecule polylactic acid microspheres are obtained. Accordingly, the preparation method is simple and easy to implement, and the feasibility of implementation is high. The morphology of polymer microspheres is regulated through a method of combining liquid-liquid separation and polymer crystallization; meanwhile, the structure and performance are regulated, and the application range is extended. Raw materials of prepared materials all come from biomass renewable resources, can be completely degraded after use, are green and environmentally friendly and have good biocompatibility. Chemical-loading particles are prepared through a chemical and polymer coprecipitation method, use of emulsifier can be effectively avoided, and then the polymer nanoparticles or microspheres have a wider application prospect.
The invention relates to the field of biomedicine, in particular to a trimerization new coronavirus receptor binding domain, and a preparation method and application thereof. The invention constructs and expresses trimerization new coronavirus RBD. The target fragment is connected to a pFastBac1 vector, and the recombinant bacmid is obtained after the target fragment is transformed into a DH10Bac competent cell. And (3) transfecting the recombinant bacmid to sf9 cells, performing virus rescue to obtain recombinant baculovirus, inoculating the recombinant baculovirus into suspension sf9 cells for 96 hours, and harvesting a culture medium for purification. PCR and WesternBlot results show that the recombinant baculovirus is successfully constructed and can successfully express the foreign protein RBD-6 HB. SDS-PAGE and WesternBlot identification are carried out on the purified protein, and the result shows that the purification effect is good, thereby laying the foundation for later vaccine and basic research.
It is important to note that the TopCare system is currently the standard of care in the MGPC-PBRN. As such, this proposal does not involve evaluating the TopCare system or the patients and providers using it. Rather, the study evaluates the part of the TopCare system that involves the automated identification and referral to PN of patients at increased risk of screening non-adherence. All eligible patients overdue for cancer screening tests will receive usual care that includes a reminder letter and referral to a scheduling delegate for follow-up. Since the TopCare system represents usual care for patients with the MGH primary care network, no patient contact will occur solely for research purposes. The study will involve randomly assigning participants overdue for screening and identified as high risk for not completing screening to early or delayed PN. The investigators believe this random assignment is ethical because PN is an extremely limited resource, and all patients in the investigators network identified as high risk for not completing screening could not be contacted by the investigators navigators in a short period of time. Thus, the investigators will randomly assign access to PN during the study period, and then allow all participants to be navigated after the study period is over. As a result, all overdue, high risk patients will be referred for PN, but the timing of the referral will be randomly assigned. In this study, the investigators objectives are to improve the algorithm to automatically identify patients who are more likely to benefit from PN (Specific Aim 1), and to evaluate the clinical impact of PN in a randomized controlled trial within the MGPC-PBRN (Specific Aim 2). Investigators will also survey all patients identified by the TopCare algorithm to assess their overall satisfaction with healthcare to determine whether PN impacts satisfaction with healthcare (Specific Aim 3).

Revising and improving the current 'high risk' algorithm to automatically identify patients who may be helped by PN in Specific Aim 1 will help us to most effectively utilize limited PN resources. The current algorithm utilizes information about patient age, number of overdue tests, primary language, and no-show visit history. The investigators will investigate adding patient registration information about insurance and education status to better identify patients at high risk for not completing screening.

In Specific Aim 2, investigators will randomize eligible patients from the MGPC-PBRN primary care practices to either Arm 1 - TopCare with PN: Patients identified as at high risk for not completing screening by the automated algorithm will be assigned to a PN list for contact to help schedule and complete screening (breast, cervical, and colon), or Arm 2 - TopCare without PN: These patients will benefit from the standard features of the TopCare system, including automated identification of overdue patients, patient reminder letters, and referral to a scheduling delegate. All high risk patients in this arm will be eligible for PN after the study period is over.
Assessment of measurable residual disease (MRD) provides important prognostic information and can inform decision-making about appropriate consolidative therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Many contemporary treatment protocols for Ph+ ALL achieve high rates of MRD negativity, and several analyses suggest that allogeneic hematopoietic stem cell transplant in first remission can be safely deferred in most patients who achieve MRD negativity by PCR for BCR::ABL1 within 3 months. Given the close association between achievement of MRD negativity and favorable long-term outcomes in Ph+ ALL, MRD response rates may aid in the evaluation of novel regimens, particularly in the absence of randomized data or robust survival data. While most studies in Ph+ ALL have used PCR for BCR::ABL1 to measure MRD and correlate with outcomes, this assay has several limitations. PCR or next-generation sequencing-based assays for immunoglobin or T-cell receptor (IG/TR) gene rearrangements may provide a more accurate assessment of clinically significant MRD in Ph+ ALL, particularly in patients with multilineage involvement of BCR::ABL1. Herein, we discuss the prognostic and therapeutic role of MRD in Ph+ ALL. We review the available methods of MRD assessment in Ph+ ALL and discuss the advantages of MRD assays that track IG/TR rearrangements rather than BCR::ABL1.
Drug: RC48-ADC 2.0 mg/kg (HER2 Positive) 32 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
In addition to mirror therapy, Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facilitation techniques, which are traditional physical therapy and rehabilitation methods, will be applied to the control group. In addition, a virtual environment monitoring session will be conducted in non-interactive virtual environments for 10 minutes after their treatment.
Stable aqueous solutions of riboflavin are obtained by incorporating therein a lower aliphatic (e.g. ethyl or propyl) hydroxy amide of gentisic acid.  Additional vitamins, e.g. vitamin B1, niacinamide, pantothenic acid and vitamin C may be added.  Gentisic acid amides may be obtained by reacting a gentisic acid ester, e.g. methyl or ethyl gentisate, with a lower aliphatic hydroxy amine, e.g. monoethanolamine or isopropanolamine.ALSO:Stable aqueous solutions of riboflavin are obtained by incorporating therein a lower aliphatic (e.g. ethyl or propyl) hydroxy amide of gentisix acid.  Additional vitamins, e.g. vitamin B, niacinamide, pantothenic acid and vitamin C may be added.
Heterotopic ossification (HO) in tendons can lead to increased pain and poor tendon function. Although it is believed to share some characteristics with bone, the structural and elemental compositions of HO deposits have not been fully elucidated. This study utilizes a multimodal and multiscale approach for structural and elemental characterization of HO deposits in healing rat Achilles tendons at 3, 6, 12, 16, and 20 weeks post transection. The microscale tomography and scanning electron microscopy results indicate increased mineral density and Ca/P ratio in the maturing HO deposits (12 and 20 weeks), when compared to the early time points (3 weeks). Visually, the mature HO deposits present microstructures similar to calcaneal bone. Through synchrotron-based X-ray scattering and fluorescence, the hydroxyapatite (HA) crystallites are shorter along the c-axis and become larger in the ab-plane with increasing healing time, while the HA crystal thickness remains within the reference values for bone. At the mineralization boundary, the overlap between high levels of calcium and prominent crystallite formation was outlined by the presence of zinc and iron. In the mature HO deposits, the calcium content was highest, and zinc was more present internally, which could be indicative of HO deposit remodeling. This study emphasizes the structural and elemental similarities between the calcaneal bone and HO deposits.
Despite low prevalence of leprosy worldwide, new cases continue to present and require swift evaluation and diagnosis to prevent complications. Here, we describe a case of lepromatous leprosy with Lucio's phenomenon initially presenting with facial and periorbital edema. A 38-year-old Brazilian woman presented to the emergency department with facial swelling and erythema, initially treated as cellulitis. Due to rapid worsening despite broad-spectrum antibiotics, she underwent soft tissue exploration and biopsy due to concern for necrotizing fasciitis. During her course, she also developed retiform purpura of bilateral upper and lower extremities. Periorbital and lower extremity pathological specimens ultimately revealed acid-fast bacilli consistent with Mycobacterium leprae , and the patient improved with multidrug therapy. This case illustrates the diagnostic difficulty of lepromatous leprosy with Lucio's phenomenon, which can initially present with periorbital edema.